These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1370199)

  • 21. Production of lymphokine-activated lymphocytes. Lysis of human head and neck squamous cell carcinoma cell lines.
    Alessi DM; Hutcherson RW; Mickel RA
    Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):725-30. PubMed ID: 2785809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of squamous cell carcinoma of the head and neck with combined methotrexate and irradiation.
    Friedman M; DeNarvaes FN; Daly JF
    Cancer; 1970 Sep; 26(3):711-21. PubMed ID: 5458276
    [No Abstract]   [Full Text] [Related]  

  • 24. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.
    Urba SG; Forastiere AA; Wolf GT; Amrein PC
    Cancer; 1993 Apr; 71(7):2326-31. PubMed ID: 8453554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer.
    Wanebo HJ; Blackinton D; Kouttab N; Mehta S
    Am J Surg; 1993 Oct; 166(4):389-94. PubMed ID: 8214299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma.
    Richtsmeier WJ; Koch WM; McGuire WP; Poole ME; Chang EH
    Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1271-7. PubMed ID: 2122909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
    Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
    J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
    Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
    Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of IL-2 injection around the metastatic cervical lymphnode].
    Ogasawara H; Takeda N; Takeda N; Kumoi T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1119-22. PubMed ID: 2398297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A phase 2 study of recombinant interleukin 2 (S-6820) for head and neck cancer].
    Sawaki S
    Gan No Rinsho; 1990 Feb; 36(2):111-20. PubMed ID: 2308207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2.
    Sacchi M; Vitolo D; Sedlmayr P; Rabinowich H; Johnson JT; Herberman RB; Whiteside TL
    Int J Cancer; 1991 Mar; 47(5):784-91. PubMed ID: 2004859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.
    Strasnick B; Lagos N; Lichtenstein A; Mickel RA
    Otolaryngol Head Neck Surg; 1990 Oct; 103(4):537-49. PubMed ID: 2123311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx.
    Barkley HT; Fletcher GH; Jesse RH; Lindberg RD
    Am J Surg; 1972 Oct; 124(4):462-7. PubMed ID: 5076159
    [No Abstract]   [Full Text] [Related]  

  • 38. [The observation on treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer].
    Han D; Zhu X; Huang Z
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):454-6. PubMed ID: 10920882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Maihoefer C; Schüttrumpf L; Macht C; Pflugradt U; Hess J; Schneider L; Woischke C; Walch A; Baumeister P; Kirchner T; Zitzelsberger H; Belka C; Ganswindt U
    Radiat Oncol; 2018 Jul; 13(1):123. PubMed ID: 29970111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killer cells and metastases from pharyngeal carcinoma.
    Schantz SP; Savage HE; Racz T; Taylor DL; Sacks PG
    Am J Surg; 1989 Oct; 158(4):361-6. PubMed ID: 2802042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.